Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Whalewatcher1on Dec 28, 2021 8:55am
69 Views
Post# 34265140

RE:RE:RE:RE:RE:Whalewatcher1 when you're going for the jugular don't miss!

RE:RE:RE:RE:RE:Whalewatcher1 when you're going for the jugular don't miss!Dude, we are in agreement $15 Million USD threshold is for the actual uplist. What I don't think you understand is that this company is already traded on CSE and OTC, an uplisting remains dual listed. You CANNOT suddenly change the value of what's being traded on CSE because graduate from otc to Nasdaq. Your example doesn't make sense as the company wasn't listed on another exchange . Just go lookup all the Canadian companies who have uplisted to Nasdaq while on Canadian exchange or go ask your broker how it works. I fear this is being setup for failure as doesn't appear they will meet min listing requirements without a $10m plus capital raise on a $5m valuation which wipes everyone out again. If that size of raise occurs at large discount, is another consolidation needed? The consolation was done to uplist. Also do you really think Nasdaq will accept a new listing with a company with $3M cash and $8m annual cash expense and traded at $5M market cap?
<< Previous
Bullboard Posts
Next >>